MacroGenics (MGNX)
(Delayed Data from NSDQ)
$14.56 USD
+0.19 (1.32%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.54 -0.02 (-0.14%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 341 - 360 ( 360 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
Competitor''s Breakthrough Therapy Designation Bodes Well for The DART''s
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
MGD006 Becomes First DART to Enter Clinic, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
We initiate with a Buy rating and a $28 price target
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Transitioning Coverage; MGD010 DART Partnered with Takeda, Reiterate OUTPERFORM while Reducing PT to $52
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
LIFE SCIENCES AND HEALTH CARE: The Week Ahead in Life Sciences - Upcoming Events for the Week of May 5
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MacroGenics, Inc.
Industry: Medical - Products
Preclinical Data of MGD007 Demonstrate Anti- Tumor Activity in the Colorectal Cancer Setting
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: MacroGenics, Inc.
Industry: Medical - Products
Preclinical Data of MGD007 Demonstrate Anti- Tumor Activity in the Colorectal Cancer Setting
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
ASH Wrap up -- MGD006 pre-clinical oral presentation highlights potency of this CD3 IL-3R DART
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: MacroGenics, Inc.
Industry: Medical - Products
ASH Wrap up -- MGD006 pre-clinical oral presentation highlights potency of this CD3 IL-3R DART
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: MacroGenics, Inc.
Industry: Medical - Products
Initiating Coverage with an OUTPERFORM Rating and $70 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G